In short
Zipalertinib is an investigational drug being studied in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC), particularly in patients with specific EGFR mutations. These trials aim to evaluate the safety and efficacy of Zipalertinib alone or in combination with chemotherapy, compared to standard treatments. The studies focus on patients with EGFR exon 20 insertion mutations and other uncommon EGFR mutations, offering hope for improved outcomes in this challenging subset of lung cancer patients.
At a glance
- Drug Name
- Zipalertinib (TAS6417/CLN-081)
- Target Condition
- Advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations or other uncommon EGFR mutations
- Trial Phases
- Phase 2b and Phase 3
- Treatment Approaches
- 1. Zipalertinib monotherapy 2. Zipalertinib in combination with chemotherapy (pemetrexed and platinum agent)
- Key Endpoints
- 1. Objective Response Rate (ORR) 2. Progression-Free Survival (PFS) 3. Overall Survival (OS) 4. Safety and tolerability 5. Intracranial efficacy for patients with brain metastases
- Patient Populations
- 1. Previously treated patients 2. Treatment-naive patients 3. Patients with brain metastases
- Administration
- Oral tablet, daily dosing
- Unique Features
- 1. Focus on EGFR exon 20 insertion mutations 2. Inclusion of patients with brain metastases 3. Evaluation of intracranial efficacy
What is Zipalertinib?
Zipalertinib, also known as TAS6417 or CLN-081, is an investigational medication being developed for the treatment of advanced non-small cell lung cancer (NSCLC). It is specifically designed to target certain genetic mutations in lung cancer cells, offering a potential new treatment option for patients with specific types of NSCLC.
How Does Zipalertinib Work?
Zipalertinib belongs to a class of drugs called EGFR tyrosine kinase inhibitors (TKIs). It works by targeting and blocking the activity of a specific protein called the epidermal growth factor receptor (EGFR) when it has certain mutations. By inhibiting this protein, zipalertinib can potentially slow down or stop the growth of cancer cells that depend on these mutated EGFR proteins to survive and multiply.
Who Can Benefit from Zipalertinib?
Zipalertinib is being studied for patients with advanced or metastatic NSCLC who have specific EGFR mutations, particularly:
- EGFR exon 20 insertion mutations: These are less common mutations that are often resistant to existing EGFR-targeted therapies.
- Uncommon single or compound EGFR mutations: These are rarer mutations that may not respond well to current treatments.
Patients with brain metastases (cancer that has spread to the brain) from NSCLC may also be eligible for treatment with zipalertinib in certain clinical trials.
Clinical Trials and Research
Zipalertinib is currently being evaluated in several clinical trials to assess its safety and effectiveness. Two notable studies include:
- A Phase 3 trial comparing zipalertinib plus chemotherapy to chemotherapy alone in patients with previously untreated, advanced NSCLC with EGFR exon 20 insertion mutations. This study aims to determine if adding zipalertinib to standard chemotherapy can improve outcomes for patients.
- A Phase 2b trial evaluating zipalertinib in patients with advanced NSCLC who have EGFR exon 20 insertion mutations or other uncommon EGFR mutations. This study includes patients who may have received prior treatments and those with brain metastases.
These trials are designed to measure how well zipalertinib works by looking at factors such as:
- Objective response rate (ORR): The percentage of patients whose tumors shrink or disappear with treatment.
- Progression-free survival (PFS): How long patients live without their cancer getting worse.
- Overall survival (OS): How long patients live overall.
- Intracranial efficacy: How well the drug works against brain metastases.
Potential Side Effects
As with all medications, zipalertinib may cause side effects. While the full safety profile is still being studied, some potential side effects based on similar drugs in its class may include:
- Skin rash or dryness
- Diarrhea
- Fatigue
- Decreased appetite
- Nausea
It's important to note that the clinical trials are closely monitoring for any adverse events to ensure patient safety. Patients participating in these trials will be carefully watched for any side effects and will receive appropriate medical care.
Administration and Dosage
Zipalertinib is taken orally in the form of tablets. The exact dosage and schedule are still being determined through clinical trials. In the studies mentioned, the maximum daily dose being tested is 100 mg. However, it's important to remember that the optimal dose may change based on the results of these trials.
Patients should always follow their doctor's instructions regarding medication use and report any side effects or concerns promptly.